Puberty blocker trial will help reduce harm, says Cass report author
Dr. Hilary Cass, author of a landmark review on gender medicine, argues that a clinical trial for puberty blockers is essential to reduce harm to children. She suggests that without regulated research, children may continue to access dangerous, unregulated treatments.
Why it matters
The debate over gender-affirming care for minors is a major public health and social policy issue with significant ethical implications.
Share Save Add as preferred on Google Alison Holt , Social affairs editor and James Melley , Senior social affairs producer BBC Dame Hilary Cass says puberty blocker trial is "essential" A trial examining the risks or benefits of drugs that can delay puberty for gender-questioning children will help reduce harm, according to the author of a landmark review.
The article presents the perspective of the medical expert while acknowledging the controversy and political pressure surrounding the trial.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in